DK1505992T3 - Fremgangsmåde til reduktion af smerter ved hjælp af oncolytiske vira - Google Patents

Fremgangsmåde til reduktion af smerter ved hjælp af oncolytiske vira

Info

Publication number
DK1505992T3
DK1505992T3 DK03722131T DK03722131T DK1505992T3 DK 1505992 T3 DK1505992 T3 DK 1505992T3 DK 03722131 T DK03722131 T DK 03722131T DK 03722131 T DK03722131 T DK 03722131T DK 1505992 T3 DK1505992 T3 DK 1505992T3
Authority
DK
Denmark
Prior art keywords
oncolytic viruses
reducing pain
pain
oncolytic
reducing
Prior art date
Application number
DK03722131T
Other languages
Danish (da)
English (en)
Inventor
Donald Morris
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1505992T3 publication Critical patent/DK1505992T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03722131T 2002-05-09 2003-05-07 Fremgangsmåde til reduktion af smerter ved hjælp af oncolytiske vira DK1505992T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29
PCT/CA2003/000674 WO2003094938A1 (en) 2002-05-09 2003-05-07 Method for reducing pain using oncolytic viruses

Publications (1)

Publication Number Publication Date
DK1505992T3 true DK1505992T3 (da) 2008-10-06

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03722131T DK1505992T3 (da) 2002-05-09 2003-05-07 Fremgangsmåde til reduktion af smerter ved hjælp af oncolytiske vira

Country Status (19)

Country Link
US (2) US20040091458A1 (enExample)
EP (1) EP1505992B1 (enExample)
JP (1) JP5241059B2 (enExample)
AR (1) AR039986A1 (enExample)
AT (1) ATE404213T1 (enExample)
AU (1) AU2003229431B8 (enExample)
BR (1) BR0309825A (enExample)
CA (1) CA2484398C (enExample)
DE (2) DE03722131T1 (enExample)
DK (1) DK1505992T3 (enExample)
ES (1) ES2239928T3 (enExample)
IL (1) IL164695A (enExample)
MX (1) MXPA04011007A (enExample)
NZ (1) NZ536102A (enExample)
PT (1) PT1505992E (enExample)
SI (1) SI1505992T1 (enExample)
TR (1) TR200501460T3 (enExample)
TW (1) TWI316405B (enExample)
WO (1) WO2003094938A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AU2010242748B2 (en) * 2009-05-01 2015-07-23 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
CA2990133A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1505992A1 (en) 2005-02-16
NZ536102A (en) 2008-01-31
BR0309825A (pt) 2005-03-01
CA2484398C (en) 2014-01-21
DE03722131T1 (de) 2005-09-15
ATE404213T1 (de) 2008-08-15
AU2003229431B8 (en) 2009-07-02
AU2003229431A1 (en) 2003-11-11
US20040091458A1 (en) 2004-05-13
EP1505992B1 (en) 2008-08-13
JP2005526124A (ja) 2005-09-02
PT1505992E (pt) 2008-10-06
AR039986A1 (es) 2005-03-09
WO2003094938A1 (en) 2003-11-20
DE60322885D1 (de) 2008-09-25
ES2239928T1 (es) 2005-10-16
IL164695A0 (en) 2005-12-18
IL164695A (en) 2010-12-30
SI1505992T1 (sl) 2009-02-28
HK1070565A1 (en) 2005-06-24
TW200402305A (en) 2004-02-16
JP5241059B2 (ja) 2013-07-17
CA2484398A1 (en) 2003-11-20
AU2003229431B2 (en) 2008-01-17
TWI316405B (en) 2009-11-01
TR200501460T3 (tr) 2005-06-21
US20080081032A1 (en) 2008-04-03
ES2239928T3 (es) 2009-02-16
MXPA04011007A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
ATE506104T1 (de) Hepatitis-c-virus-hemmer
DK2204374T3 (da) Nucleosidphosphonater og analoge deraf til behandling af HPV-infektioner
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1978747T3 (da) Fremgangsmåde til fjernelse af kodningsforvrængning
IS7851A (is) 1-asýl-pýrrólídínafleiður til að meðhöndla veirusýkingar
DK1585630T3 (da) Fremgangsmåde til ekstraktion af kontaktlinser
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1545217T3 (da) Induktion af genekspression ved anvendelse af en højkoncentrationssukkerblanding
IS8475A (is) Lifrarbólgu C-veirutálmar
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
NO20040322L (no) Virus-polymerase-inhibitorer
DK1608634T3 (da) Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin
IS7426A (is) Veirulíkar agnir af mennskri vörtuveiru
DK1692295T3 (da) Immobilisering af enzymer ved template-styret silikatpræcipitation
DK1525278T3 (da) Fremgangsmåde til behandling af en overflade
DK1505992T3 (da) Fremgangsmåde til reduktion af smerter ved hjælp af oncolytiske vira
DK1732604T3 (da) Fremgangsmåder til behandling af hiv-infektion
DK1709075T3 (da) Behandling af virusinfektioner
DK1412486T3 (da) Fremgangsmåde til virusformering
DK1539200T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK1536796T3 (da) N-arylpiperidinsubstituerede biphenylcarboxamider som inhibitorer af apolipoprotein B-sektion
DK1474689T3 (da) Fremgangsmåde til diagnosticering af inflammatoriske sygdomme ved anvendelse af calgranulin c